Advertisement Pharmaceutical Business review - Page 17 of 5253 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 10, 2025

Health Canada approves Biogen’s Zurzuvae for PPD treatment

Biogen has received a notice of compliance (NOC) from Health Canada for Zurzuvae (zuranolone), a neuroactive steroid (NAS), as a treatment for moderate or severe postpartum depression (PPD) in women.

Continue
The once-daily oral therapy is intended for the treatment of PPD. Credit: Iryna Imago/Shutterstock.com.
December 10, 2025

Formycon and Zydus sign exclusive agreement for FYB206 supply

The therapy is nearing the end of clinical development, with primary endpoint outcomes anticipated in the first quarter of 2026. Credit: Wasan Tita/Shutterstock.com.
December 9, 2025

EC approves Roche’s Gazyva to treat active lupus nephritis

Lupus nephritis mainly impacts women of colour and of childbearing age, with up to 135,000 sufferers in the EU. Credit: Peakstock/Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Inductive Bio gains $21m ARPA-H funds for drug prediction models
  2. Viatris signs agreements with Biocon on $815m stake sale
  3. Agilent and Monash University Malaysia to set up biodiscovery hub
  4. Denali makes $275m funding agreement with Royalty Pharma
  5. Takeda and Innovent fulfil close conditions for ADC and IO therapies

PRESS RELEASES

Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities
Gerresheimer at CPHI Frankfurt 2025
Gerresheimer at CPHI Frankfurt 2025
Pharmaceutical Business Review
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds

Suppliers

Whitepapers

Pharmaceutical Business Review
EVERIC® Pure – The Safe Option Right from the Start
Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme